Tiziana Intends To Redomicile To Bermuda
Tiziana Life Sciences intends to redomicile the company to Bermuda.
This is according to a statement on the company’s website, which said, “Tiziana Life Sciences plc, a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has appointed advisers in relation to an intended redomicile of the Company to Bermuda which is anticipated to occur by Q2-2020, as a consequence of the redomicile the Company will not be seeking to re-admit its ordinary shares on AIM and will therefore seek shareholder consent for its shares to be cancelled from AIM when the redomicile occurs. A further announcement will be made in due course.
“Furthermore, the Company intends to cancel its ADR program and have its Bermuda common shares listed on Nasdaq.”
